Caption Management’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.74M Sell
221,800
-401,200
-64% -$10.7M 0.04% 440
2025
Q4
$18M Buy
623,000
+164,400
+36% +$2.15M 0.12% 197
2025
Q3
$3.31M Sell
458,600
-438,900
-49% -$3.23M 0.03% 637
2025
Q2
$8.91M Buy
897,500
+797,500
+798% +$8.42M 0.1% 236
2025
Q1
$949K Sell
100,000
-278,000
-74% -$3.86M 0.01% 939
2024
Q4
$5.22M Sell
378,000
-434,900
-53% -$7.62M 0.05% 354
2024
Q3
$12.4M Buy
812,900
+682,400
+523% +$3.38M 0.2% 123
2024
Q2
$622K Buy
+130,500
New +$728K 0.01% 770

Other funds holding CAPR

Caption Management's CAPR Position: Q2 2025 in Review

Caption Management sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 140,000 shares — an estimated $1.48M sold.

Caption Management first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $1.33M in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Caption Management reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 140,000 Capricor Therapeutics shares in Q2 2025, an estimated $1.48M.
  • Caption Management first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
  • Caption Management's Capricor Therapeutics position peaked at $1.33M in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.